SCHEMBL2051707

SCHEMBL2051707

CCN(CCO)CCCOc1cc2ncnc(Nc3cnn(CC(=O)Nc4cccc(F)c4)c3)c2cc1OC

nearest known ligand 0.78

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FLT4 P35916 5/20 0.78
PDGFRB P09619 4/20 0.78
FLT3 P36888 4/20 0.78
AURKA O14965 12/20 0.78
AURKB Q96GD4 6/20 0.70
CSF1R P07333 2/20 0.60
EGFR P00533 4/20 0.55
KDR P35968 3/20 0.55
CSK P41240 2/20 0.55
PLK4 O00444 1/20 0.55
CIT O14578 1/20 0.55
MUSK O15146 1/20 0.55
EPHB6 O15197 1/20 0.55
MAP3K7 O43318 1/20 0.55
RIPK2 O43353 1/20 0.55
STK10 O94804 1/20 0.55
MAP4K4 O95819 1/20 0.55
CHEK2 O96017 1/20 0.55
ABL1 P00519 1/20 0.55
ERBB2 P04626 1/20 0.55

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2052845 0.97 FLT4 (0.82) FLT4PDGFRBFLT3AURKAAURKB
SCHEMBL2049092 0.96 FLT4 (0.78) FLT4PDGFRBFLT3AURKAAURKB
SCHEMBL2048681 0.96 FLT4 (0.81) FLT4PDGFRBFLT3AURKAAURKB
SCHEMBL3429103 0.96 FLT4 (0.83) FLT4PDGFRBFLT3AURKAAURKB
SCHEMBL2053127 0.94 FLT4 (0.77) FLT4PDGFRBFLT3AURKAAURKB
SCHEMBL2051886 0.94 FLT4 (0.77) FLT4PDGFRBFLT3AURKAAURKB
SCHEMBL3425987 0.94 AURKA (0.69) FLT4PDGFRBFLT3AURKAAURKB
SCHEMBL2052261 0.93 FLT4 (0.75) FLT4PDGFRBFLT3AURKAAURKB
SCHEMBL2053240 0.93 FLT4 (0.75) FLT4PDGFRBFLT3AURKAAURKB
SCHEMBL2053597 0.92 FLT4 (0.74) FLT4PDGFRBFLT3AURKAAURKB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
JP-4709139-B2 2011-06-22 JP claimed
US-7691867-B2 Chemical compounds ASTRAZENECA AB (SE) 2010-04-06 US claimed
EP-1613619-B1 QUINAZOLINE DERIVATIVES FOR TREATMENT OF CANCER ASTRAZENECA AB (SE) 2008-03-26 EP claimed
US-20060270692-A1 Chemical compounds ASTRAZENECA AB (SE) 2006-11-30 US claimed
JP-2006523660-A 2006-10-19 JP claimed
EP-1613619-A1 QUINAZOLINE DERIVATIVES FOR TREATMENT OF CANCER AstraZeneca AB (SE) 2006-01-11 EP claimed
WO-2004094410-A1 CHEMICAL COMPOUNDS ASTRAZENECA AB (SE) 2004-11-04 WO claimed
US-7691867-B2 Chemical compounds ASTRAZENECA AB (SE) 2010-04-06 US disclosed
EP-1613619-B1 QUINAZOLINE DERIVATIVES FOR TREATMENT OF CANCER ASTRAZENECA AB (SE) 2008-03-26 EP disclosed
US-20060270692-A1 Chemical compounds ASTRAZENECA AB (SE) 2006-11-30 US disclosed
EP-1613619-A1 QUINAZOLINE DERIVATIVES FOR TREATMENT OF CANCER AstraZeneca AB (SE) 2006-01-11 EP disclosed
WO-2004094410-A1 CHEMICAL COMPOUNDS ASTRAZENECA AB (SE) 2004-11-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060270692-A1 Chemical compounds CCNI, MKI67, TP53 FLT4 2898/4885PDGFRB 1544/4885FLT3 703/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.